US2018010127A1PendingUtilityA1

Method of enhancing mir-185 expression to reduce low density lipoprotein/cholesterol accumulation in a cell

49
Assignee: YANG MUHUAPriority: Jun 15, 2012Filed: Jul 11, 2017Published: Jan 11, 2018
Est. expiryJun 15, 2032(~5.9 yrs left)· nominal 20-yr term from priority
Inventors:Muhua YangJoseph T. NickelsWeidong LiuChristina Ann Pellicane
C12Y 205/01021C12Y 101/01034C12Q 2600/178C12N 15/1137C12N 15/1138C12Q 1/6883C12Q 2600/158C12N 2310/141C12N 15/113
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of quantifying miR-185 as a potential biomarker in lipid disorder or cardiovascular diseases in human. The present invention also provides a method of modulating miR-185 in regulating LDL and cholesterol metabolism in cells. The present invention has therapeutic potential in the treatment of cholesterol/LDL related cardiovascular diseases in humans.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A kit for determining an increased risk for atherosclerosis in a human, comprising:
 a) a reagent for quantifying miR-185 expression level in a biological sample; and   b) an instruction for use of said reagent in quantifying said miR-185 expression level, wherein an increased miR-185 expression level is indicative of an increased risk of atherosclerosis in a human.   
     
     
         2 . The kit of  claim 1 , wherein said reagent comprises a forward primer and a reverse primer for miR-185 used in a qRT-PCR to specifically quantify the expression level of miR-185. 
     
     
         3 . The kit of  claim 1 , wherein said biological sample is blood.

Join the waitlist — get patent alerts

Track US2018010127A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.